HopeStage
Back to all studies
CompletedNCT02970292

Pimavanserin Added to Treatment for Schizophrenia: A Placebo-Controlled Trial

About this titleRead the official source — NCT02970292

This study evaluated the safety and effectiveness of Pimavanserin for people with schizophrenia.

Medication studyAges 18–55Multiple countries
The study in practice

Understand this study

What did researchers investigate?

This study evaluated the safety and effectiveness of Pimavanserin for people with schizophrenia.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.

Listed locations
Phoenix and 104 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: October 26, 2016
Recruitment status
Completed
Enrollment listed in the registry
396
Sponsor
ACADIA Pharmaceuticals Inc.
Sponsor type
Other organization
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, Canada, Bulgaria, ...
Age range
From 18 Years to 55 Years
Official registry ID
NCT02970292
Official title
Show the full official title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Phoenix, United States · Little Rock, United States · Rogers, United States

81 more locations
  • Bellflower, United States
  • Cerritos, United States
  • Culver City, United States
  • Lemon Grove, United States
  • Long Beach, United States
  • San Diego, United States
  • Santa Ana, United States
  • Torrance, United States
  • Boca Raton, United States
  • Lauderhill, United States
  • Miami, United States
  • Atlanta, United States
  • Chicago, United States
  • Hoffman Estates, United States
  • Lake Charles, United States
  • Catonsville, United States
  • Ann Arbor, United States
  • Las Vegas, United States
  • Berlin, United States
  • Cedarhurst, United States
  • Jamaica, United States
  • Rochester, United States
  • Charlotte, United States
  • Dayton, United States
  • Charleston, United States
  • Richardson, United States
  • Salt Lake City, United States
  • Burgas, Bulgaria
  • Pazardzhik, Bulgaria
  • Plovdiv, Bulgaria
  • Sofia, Bulgaria
  • Targovishte, Bulgaria
  • Tserova Koria, Bulgaria
  • Varna, Bulgaria
  • Veliko Tarnovo, Bulgaria
  • Vratsa, Bulgaria
  • Chatham, Canada
  • Montreal, Canada
  • Toronto, Canada
  • Hradec Králové, Czechia
  • Pilsen, Czechia
  • Prague, Czechia
  • Říčany, Czechia
  • Kalocsa, Hungary
  • Budapest, Hungary
  • Debrecen, Hungary
  • Pécs, Hungary
  • Kaunas, Lithuania
  • Šilutė, Lithuania
  • Vilnius, Lithuania
  • Bialystok, Poland
  • Bydgoszcz, Poland
  • Lublin, Poland
  • Pruszcz Gdański, Poland
  • Roshchino, Russia
  • Plekhanovo, Russia
  • Tonnel’nyy, Russia
  • Arkhangelsk, Russia
  • Moscow, Russia
  • Saint Petersburg, Russia
  • Samara, Russia
  • Smolensk, Russia
  • Stavropol, Russia
  • Voronezh, Russia
  • Yaroslavl, Russia
  • Belgrade, Serbia
  • Kovin, Serbia
  • Kragujevac, Serbia
  • Niš, Serbia
  • Kherson, Ukraine
  • Dnipro, Ukraine
  • Hlevakha, Ukraine
  • Kharkiv, Ukraine
  • Kyiv, Ukraine
  • Odesa, Ukraine
  • Oleksandrivka, Ukraine
  • Poltava, Ukraine
  • Smila, Ukraine
  • Vinnytsia, Ukraine
  • Czechia
  • Russia

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

This study evaluated the safety and effectiveness of Pimavanserin for people with schizophrenia.

Who is behind this study?

The study sponsor is ACADIA Pharmaceuticals Inc.

Did this study involve medication?

Yes. The study involved medication, including Pimavanserin and Placebo.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies